Cipla’s arm recalling over 400 cartons of Nilotinib Capsules due to manufacturing issue

09 Mar 2026 Evaluate

Cipla’s wholly owned subsidiary -- Cipla USA, Inc is recalling over 400 cartons of generic anti-cancer medication, Nilotinib Capsules, due to a manufacturing issue. Cipla USA, Inc has recalled Nilotinib Capsules in two strengths (150 mg and 200 mg). 

On February 18, 2026, Cipla USA, Inc had initiated the Class III voluntary recall. A Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).

Cipla Share Price

1325.15 3.40 (0.26%)
09-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.60
Dr. Reddys Lab 1286.40
Cipla 1325.15
Zydus Lifesciences 908.65
Lupin 2301.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×